Wildi

Argentina Australia Brazil Germany Hong Kong Italy Japan South Africa Spain United States of America Ireland
|
2020
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Immunomodulator
  • Antineoplastic agent
  • Imatinib
  • Infliximab

PHOSP-COVID

United Kingdom
|
2020
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19

LUNGTERMcov

Switzerland
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19

López-González

Spain
|
2021
  • Adults (18-64 years)
  • General population
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19

COVIXTREM

Spain
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • Outpatient clinic
  • Intensive care unit
  • SARS-CoV-2
  • Acute COVID-19
  • Blood sample